ADC TherapeuticsADCT
ADCT
About: ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Employees: 263
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
24% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 21
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
0% more funds holding
Funds holding: 83 [Q4 2024] → 83 (+0) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
3.07% less ownership
Funds ownership: 58.43% [Q4 2024] → 55.36% (-3.07%) [Q1 2025]
31% less capital invested
Capital invested by funds: $112M [Q4 2024] → $77.3M (-$35.1M) [Q1 2025]
36% less call options, than puts
Call options by funds: $7K | Put options by funds: $11K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
123%
upside
Avg. target
$8.67
142%
upside
High target
$10
179%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Michael Schmidt | 179%upside $10 | Buy Maintained | 13 Jun 2025 |
RBC Capital Gregory Renza | 123%upside $8 | Outperform Reiterated | 15 May 2025 |
HC Wainwright & Co. Robert Burns | 123%upside $8 | Buy Reiterated | 31 Mar 2025 |
Financial journalist opinion
Based on 3 articles about ADCT published over the past 30 days
Neutral
PRNewsWire
3 days ago
ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028
LAUSANNE, Switzerland , June 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $100.0 million private investment in public equity ("PIPE") financing. In the PIPE, ADC Therapeutics is selling 13.0 million common shares at $3.53 per share and pre-funded warrants to purchase 15.7 million common shares at $3.43, per pre-funded warrant, which is the price per common share in the PIPE minus the exercise price of CHF 0.08 per pre-funded warrant.
Neutral
PRNewsWire
3 days ago
ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress
ZYNLONTA® in combination with glofitamab (COLUMVI®) in patients with r/r DLBCL demonstrated clinically meaningful benefit with overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% across 30 efficacy evaluable patients 25 of 26 patients achieving CR remained in CR as of the data cut-off Initial data show the combination is generally well tolerated with a manageable safety profile Company expanding enrollment for LOTIS-7 to 100 patients at 150 µg/kg dose Company to host conference call today at 8:00 a.m. ET/2:00 p.m.
Neutral
PRNewsWire
1 week ago
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland , June 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 107,550 of the Company's common shares to two new employees on June 2, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.
Neutral
PRNewsWire
1 month ago
ADC Therapeutics to Present at Upcoming Investor Conferences
LAUSANNE, Switzerland , May 15, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two upcoming investor conferences: RBC Capital Markets Global Healthcare ConferenceDate: May 21, 2025 Presentation Time: 10:30-10:55 a.m. ET Format: Fireside ChatSpeaker: Ameet Mallik, Chief Executive OfficerTo register for the webcast, click here.
Neutral
Seeking Alpha
1 month ago
ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call Transcript
ADC Therapeutics SA (NYSE:ADCT ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Corporate Participants Marcy Graham - Investor Relations Officer Ameet Mallik - Chief Executive Officer Mohamed Zaki - Chief Medical Officer Pepe Carmona - Chief Financial Officer Conference Call Participants Eric Schmidt - Cantor Sudan Loganathan - Stephens Operator Good morning, ladies and gentlemen, and welcome to ADC Therapeutics' First Quarter 2025 Earnings Call. [Operator Instructions] I would now like to turn the conference call over to Marcy Graham, Investor Relations and Corporate Affairs Officer.
Negative
Zacks Investment Research
1 month ago
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.56 per share a year ago.
Neutral
PRNewsWire
1 month ago
ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update
LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML); ZYNLONTA® plus glofitamab demonstrated ORR of 95.5% and CR of 90.9% with encouraging safety and tolerability Forty patient enrollment reached in LOTIS-7 trial dose expansion arm in patients with relapsed/refractory DLBCL Cash runway expected to fund multiple catalysts into the second half of 2026 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland , May 14, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the first quarter ended March 31, 2025, and provided recent operational updates.
Neutral
PRNewsWire
1 month ago
ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)
ZYNLONTA ® plus glofitamab (COLUMVI®) demonstrated ORR of 95.5% and CR of 90.9%, among 22 evaluable patients with relapsed/refractory DLBCL Safety and tolerability data were consistent with the known profiles of each agent Updated data to be shared during poster presentation at EHA2025 on Saturday, June 14 at 12:30 p.m. ET and oral presentation at ICML on Friday, June 20 at 9:00 a.m.
Neutral
PRNewsWire
1 month ago
ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025
LAUSANNE, Switzerland , May 8, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 8:30 a.m. EDT to report financial results for the first quarter 2025 and provide operational updates.
Negative
Zacks Investment Research
1 month ago
ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
ADC Therapeutics (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charts implemented using Lightweight Charts™